Core Viewpoint - The company, Chaoyou Ophthalmology (02219), experienced a significant decline in stock price by 12% following the release of its mid-term results for 2025, indicating challenges in revenue and profit performance [1] Financial Performance - The company reported revenue of 698 million HKD, representing a year-on-year decrease of 4.91% [1] - The profit attributable to the parent company was 114 million HKD, down 16.72% compared to the previous year [1] - The company announced that it would not declare an interim dividend [1] Operational Challenges - The decline in revenue was primarily attributed to a slight decrease in outpatient and inpatient visits, which are mainly focused on basic ophthalmic services [1] - The company is facing intensified market competition and is responding to the national policy of volume-based procurement (VBP) in China by implementing internal pricing adjustments starting in the second half of 2024 [1]
港股异动 | 朝聚眼科(02219)跌12% 上半年纯利同比减少16.72%至1.14亿元